Comparison of T-Cell Subsets' Reconstitution After 12 Months of Highly Active Antiretroviral Therapy Initiated During Early Versus Advanced States of HIV Disease
- 1 December 2000
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 25 (4) , 296-305
- https://doi.org/10.1097/00042560-200012010-00002
Abstract
This research comprised a pilot open prospective clinical study comparing T-cell subset reconstitution in antiretroviral-naive patients, after 12 months of HAART when treatment was initiated in early stages (ES; n = 18) of infection versus advanced stages (AS; n = 20).10 healthy HIV-negative individuals. Immunophenotypic markers were evaluated before and after 6-and 12-months' therapy. Functional assays were performed in one subset.Viral load (VL) was < 200 copies/ml in all patients. Median percentages of CD4+ pretherapy were 33% and 6%, respectively, in the ES and AS groups, increment after 12 months of therapy was +15% and +13% respectively. Only the ES group achieved normal values. Declines of CD8+ percentage were significantly higher in the ES (-18%) than in the AS group (-2%). CD4+ memory and naive cells in the ES group were similar to those of controls before treatment and did not change after therapy. In contrast, CD4+ memory and naive cells in the AS group did not reach normal levels despite treatment. In the ES group, there was a significant increment in CD8+ naive cells (+8%) and a decrement in CD8+CD38+ cells (-17%), both populations reached values close to normal, whereas these subsets remained far from normal in the AS group. Improvement of lymphoproliferative response after therapy was observed in both groups. One patient in the ES group showed positive LPR against p24 after treatment. After 12 months' highly active antiretroviral therapy, only those who began such therapy in ES disease reached values within the range of healthy controls. To achieve a more complete immunologic reconstitution, early initiation of potent antiretroviral therapy should be recommended.Keywords
This publication has 26 references indexed in Scilit:
- Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 diseaseThe Lancet, 1998
- Passive Immunization with a Human Immunodeficiency Virus Type 1-Neutralizing Monoclonal Antibody in Hu-PBL-SCID Mice: Isolation of a Neutralization Escape VariantThe Journal of Infectious Diseases, 1998
- Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferationNature Medicine, 1998
- Positive Effects of Combined Antiretroviral Therapy on CD4 + T Cell Homeostasis and Function in Advanced HIV DiseaseScience, 1997
- HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapiesNature Medicine, 1997
- Patterns of Virus Burden and T Cell Phenotype Are Established Early and Are Correlated with the Rate of Disease Progression in Human Immunodeficiency Virus Type 1-Infected PersonsThe Journal of Infectious Diseases, 1996
- Alterations in the Immune Response of Human Immunodeficiency Virus (HIV)-Infected Subjects Treated with an HIV-Specific Protease Inhibitor, RitonavirThe Journal of Infectious Diseases, 1996
- Toward an Understanding of the Correlates of Protective Immunity to HIV InfectionScience, 1996
- HIV pathogenesis and long-term survivalAIDS, 1993
- Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals.Proceedings of the National Academy of Sciences, 1990